News

EU patent for IML-106 granted

It is a great pleasure to have received the message from the EU Patent Office in Munich, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the EU Patent Office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.

Read More
Lars Siegert

ImmunoLogik expands management

Besides the managing director Christian Setz, Lars Siegert joins ImmunoLogik GmbH a managing director. With this step the shareholders give an important impulse for the direction of the successful development of the company with two managing directors from science and business.

Read More
Coronavirus

Start of the crowdinvesting campaign against SARS-CoV-2 on aescuvest.de

In the fight against coronaviruses the team of the ImmunoLogik identified a promising lead candidate for the treatment of people infected with SARS-CoV-2. The highly qualified ImmunoLogik Team around Dr. Christian Setz (Managing Director, formerly project leader at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) and the scientific advisor Prof. Dr. Ulrich Schubert (Professor for virology at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) present this funding project on aescuvest.de in summer 2020. Only here you have the chance to learn more about the concept, to use the information advantage and to become an investor.

Read More
Coronavirus

Preannouncment: Crowdinvesting campaign on aescuvest

In the fight against coronaviruses the team of the ImmunoLogik identified a promising lead candidate for the treatment of people infected with SARS-CoV-2.

For the funding of the next steps in the drug development of the lead candidate IML-206 the ImmunoLogik starts a new crowdinvesting campaign on aescuvest.de and moneywell.de  in the context of the #CrowdBeatsCorona alliance.

Read More

US patent for IML-106 granted

It is a great pleasure to have received the message from the USA, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the US patent office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.

Read More